Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday.

The company released patient updates on progression-free survival (PFS) and overall survival (OS) from the ongoing MAGIC-1 study of MTX110 in recurrent glioblastoma (rGBM), a form of adult brain cancer.

The study evaluates the feasibility, safety, and efficacy of treating rGBM patients with MTX110.

Also Read: Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday – Here's Why.

The company earlier reported that patients #1 and #2 in Cohort A achieved overall survival (OS) of 12 and 13 months, respectively.

The remaining two patients in Cohort A remain on follow-up.

Patient #3 has achieved 13 months of OS to date, with six months of progression-free survival (PFS).

Patient #4 has not progressed and has achieved 12 months of PFS and 12 months of OS to date.

"The interim data from the MAGIC-G1 study has raised hopes that MTX110 could provide a new treatment option that offers real benefits in survival without the toxicity associated with traditional chemotherapy," the company says.

MTX110 has been evaluated for Diffuse midline glioma (DMG), a rare but highly aggressive form of brain cancer that often affects children, in two Phase 1 trials.

A phase 1 study conducted by the University of California, San Francisco (UCSF) involved patients with DMG and reported a median overall survival of 26.1 months. This contrasts with the historical median survival of around 10 months for patients with DMG.

In a separate phase 1 trial involving newly diagnosed DMG patients at Columbia University, MTX110 demonstrated, after only two infusions per patient, similarly encouraging results, improving median overall survival to 16 months.

Price Action: BDRX stock is down 30.01% at $5.88 at the last check Thursday.

• FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year